CRC Research Update — November 18, 2026
Today's colorectal cancer research highlights
Curated CRC research, accessible, accurate, actionable
The CRC Digest
Wednesday, November 18, 2026
IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.
CRC Research Update
-
TREATMENT
FDA grants fast track designation to onvansertib plus FOLFIRI/bevacizumab for first-line RAS-mutated metastatic colorectal cancerThe oral PLK1 inhibitor combined with standard chemotherapy showed a confirmed response rate of 72.2% versus 42.1% with chemotherapy alone in the phase 2 CRDF-004 trial, representing a 30.1-percentage-point improvement in patients with KRAS- or NRAS-mutated disease. (Targeted Oncology)
-
SCREENING
Racial and ethnic disparities persist in colorectal cancer screening recommendations and uptakeAnalysis of nearly 40,000 U.S. adults found that Hispanic, non-Hispanic Black, and non-Hispanic Asian adults were significantly less likely than non-Hispanic White adults to receive provider screening recommendations, even after accounting for socioeconomic factors and insurance. (Cancer Prevention Research)
-
SCREENING
Serrated polyps account for up to 30% of colorectal cancers and are disproportionately linked to post-colonoscopy cancerA comprehensive review in Gastroenterology highlights that serrated neoplasia remains under-detected and inconsistently classified, with the sessile serrated lesion detection rate emerging as an independent predictor of post-colonoscopy colorectal cancer risk. (Gastroenterology)
-
LIVING WITH CRC
Co-designed mobile health survivorship program shows feasibility for colorectal cancer survivors after primary treatmentA pilot randomized trial of 30 survivors found a 73.3% adherence rate to the 12-week FORYOU program, with participants completing an average of 5.4 out of 6 sessions, though overall quality-of-life differences between groups were not significant. (Journal of Cancer Survivorship)
This week's research spans screening equity, molecular diagnostics, targeted therapy development, and survivorship support.
Get CRC research intelligence delivered weekly, free.
SubscribeCRC Digest
Not Medical Advice
The CRC Digest provides research summaries for informational and educational purposes only. This is not medical advice. Always consult your healthcare provider before making any decisions about your care.
Content is curated with AI assistance and reviewed by the editorial team.
Browse Past Issues · Read our full disclaimer · Manage subscription
Useful? Forward it to a colleague. Many of the topics named here have a live research dossier, trajectory and evidence, at Signal Bureau.
Got this from a colleague? Subscribe here. Readers are added at their own request, by sign-up or through Evolution Labs.
Evolution Accelerator, Inc. (dba Evolution Labs) · 3941 Park Dr., Suite 20341, El Dorado Hills, CA 95762
You are receiving this because you subscribed to CRC Digest (self-serve signup)
Unsubscribe: honored promptly, no login required. · Privacy policy · Manage or delete your data